This prestigious volume presents the findings of an international group of academic and biotechnological researchers. Topics range from early detection programs focusing on genetic factors, novel probes for detecting B-amyloid in the living brain, and the use of telephonic screening and MRI's to the diversity of therapeutic areas such as antioxidants, estrogen agonists and various anti-B-amyloid and anti-tangle approaches. The volume is still an indispensable resource for the psychogeriatrician, psychiatrist, clinical investigator, and neurobiologist, and a must for medical libraries.

Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.

The American Psychiatric Publishing Textbook of Alzheimer Disease and Other Dementias is an up-to-date and comprehensive overview of dementia for psychiatrists and other health care practitioners who deal with cognitively impaired adults in outpatient, inpatient, and long-term care settings. With content ranging from clinical guidance to basic research, it contains information on nearly every subject related to dementing conditions or illnesses -- not only providing extensive coverage of clinical management issues but also enabling a deeper understanding of the causes of dementia. Designed to assist the practitioner faced with everyday dilemmas, from dosages of antipsychotic drugs to legal and ethical issues, this textbook describes in detail the most common conditions and diseases leading to dementia and covers pharmacologic, behavioral, and environmental treatments. It also considers a broader range of cognitive disorders and impairment in order to help practitioners recognize and treat primary brain diseases and systemic disorders affecting the brain before they reach the stage of dementia. Building on the editors' earlier work The Dementias: Diagnosis, Treatment, and Research, this new book expands on its scope, with nearly twice the number of contributors -- all clinicians or researchers at the vanguard of the field. New to this edition are chapters on epidemiology, history of dementia, biomarkers for Alzheimer disease, care of the late-stage dementia patient, prevention of dementia, and chapters devoted to: Vascular cognitive impairment, emphasizing the importance of early detection with development of appropriate treatments and risk factor control Dementia with Lewy bodies and other synucleinopathies, describing differences in cognitive profile between synucleinopathies and Alzheimer disease Frontotemporal dementias, including behavioral and language variants Traumatic brain injury, distinguishing between proximal and distal effects and risk factors for dementia later in life An abundance of charts and illustrations, extensive references and additional readings, and chapter-end key points make this a practical volume for learning, while appendixes include easily administered instruments useful in daily practice for grading cognition, day-to-day function, neuropsychiatric symptoms, and quality of life. Whether used as a clinical guide or as a sourcebook on technical and scientific developments, The American Psychiatric Publishing Textbook of Alzheimer Disease and Other Dementias is an important reference for psychiatrists, neurologists, geriatricians, primary care physicians, and other health professionals who deal with cognitively impaired adults.

In Clinical Manual of Alzheimer Disease and Other Dementias, practicing psychiatrists and neurologists provide essential input into neuropsychiatric assessment and the diagnosis and treatment of a wide range of neuropsychiatric conditions, including Alzheimer disease and traumatic brain injury. The manual provides invaluable information on both evaluation/diagnosis and treatment. Case studies offer real-life clinical experiences by some of the country's leading experts in the field. Clinical Manual of Alzheimer Disease and Other Dementias Includes DSM-IV-TR cognitive disorders and addresses other cognitive syndromes and psychiatric symptoms that may confound diagnosis. Provides clinical insights into the diagnostic signs and symptoms of dementing illnesses, including Alzheimer disease, frontotemporal dementias, delirium, amnesia, and other cognitive disorders. Reviews the psychiatric syndromes that are related to dementing illnesses and deals with their treatment. Discusses the detection and management of depression in the evaluation of a person with a cognitive complaint or symptoms. Emphasizes the behavioral disorders that accompany dementing illness and presents an approach to their pharmacological and nonpharmacological management. Delineates clinical workup for medical conditions that may underly cognitive or other psychiatric symptoms. Provides an overview of clinical tools and techniques for diagnosing cognitive dysfunction, including history taking, mental status evaluation, physical and neurological examination, and neuropsychological testing. Presents an illustrated review of the most current techniques of neuroimaging in differential diagnosis. Includes key clinical points in every chapter summarizing important concepts. In addition to topics covered in the textbook, the manual includes a chapter on community resources to enable clinicians to better support patients and families through local and national organizations and agencies. This text is a must-have reference for clinical psychiatrists, resident fellows, residents in training, medical students in psychiatry rotations, clinical psychologists, and psychiatric nurses.

Frontiers in Clinical Drug Research - Alzheimer Disorders is an e-Book series concerned with Alzheimer's disease (AD) that causes dementia, or loss of brain function. The disease affects the parts of the brain that deal with memory, thought, and language. Chapters in each volume focus on (Alzheimer Disorders) drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for Alzheimer’s disease and related disorders. Frontiers in Clinical Drug Research - Alzheimer Disorders will be of particular interest to readers interested in drug therapy of this specific neurodegenerative condition and related brain disorders as the series provides relevant reviews written by experts in field of Alzheimer’s Disease research.

Alzheimer’s disease (AD) is a chronic neurodegenerative disorder characterized by progressive cognitive dysfunction and memory loss, inability to perform the activities of daily living and mood disorders. According to the so-called “amyloid cascade hypothesis”, amyloid-ß- peptide (Aß), produced by beta- and gamma- secretase-mediated cleavages of the amyloid precursor protein (APP), plays a pivotal role in the pathogenesis of AD. Aß was also shown to contribute to AD pathology by stimulating the hyperphosphorylation of tau which is responsible for the formation of neurofibrillary tangles. However, the “amyloid cascade hypothesis” was challenged by other theories which lend support to the idea that Aß is not causative but can be considered as an “innocent bystander” in AD. Although preclinical research generated impressive lines of evidence about the several intracellular mechanism(s) whose impairment leads to the onset and progression of AD, clinical research aimed at the development of new drugs capable of preventing or delaying the onset of neuronal damage in AD patients has produced limited results. The drugs currently available for the treatment of AD are acetylcholinesterase inhibitors (AChEI) and the NMDA glutamate receptor antagonist memantine. The AChEI increase acetylcholine levels in the synaptic cleft, which are reduced because of the progressive damage of cholinergic neurons in cognitive brain areas (e.g. amygdala, hippocampus, and frontal cortex), whereas memantine is used to prevent/reduce calcium-dependent excitotoxic neuronal cell death. Both classes of drugs have been shown to improve symptoms related to cognitive decline, but their effects are confined largely to patients with mild to moderate AD, in particular during the first year or so of treatment. An alternative to this symptomatic treatments involves the use of drugs that intervene in the pathogenesis of the disease. Recently, monoclonal antibodies against Aß were proposed as novel agents capable to remove Aß from the brain thus preventing neuronal damage. The research topic focuses on the preclinical and clinical evidence about the several factors that contribute to the pathogenesis of AD as well as the potential therapeutic role of new classes of drugs still under preclinical or clinical development.

With unprecedented interest in the power that the modern therapeutic armamentarium has to combat disease, the new edition of Drug Discovery and Development is an essential resource for anyone interested in understanding how drugs and other therapeutic interventions are discovered and developed, through to clinical research, registration, and market access. The text has been thoroughly updated, with new information on biopharmaceuticals and vaccines as well as clinical development and target identification. Drug discovery and development continues to evolve rapidly and this new edition reflects important changes in the landscape. Edited by industry experts Raymond Hill and Duncan Richards, this market-leading text is suitable for undergraduates and graduates undertaking degrees in pharmacy, pharmacology, toxicology, and clinical development through to those embarking on a career in the pharmaceutical industry. - Key stages of drug discovery and development - Chapters outline the contribution of individual disciplines to the overall process - Supplemented by specific chapters on different modalities - Includes coverage of Oligonucleotide therapies; cell and gene therapy - Now comes with online access on StudentConsult

Innovative approach to drug design that's more likely to result in an approvable drug product Retrometabolic drug design incorporates two distinct drug design approaches to obtain soft drugs and chemical delivery systems, respectively. Combining fundamentals with practical step-by-step examples, Retrometabolic Drug Design and Targeting gives readers the tools they need to take full advantage of retrometabolic approaches in order to develop safe and effective targeted drug therapies. The authors, both pioneers in the fields of soft drugs and retrometabolic drug design, offer valuable ideas, approaches, and solutions to a broad range of challenges in drug design, optimization, stability, side effects, and toxicity. Retrometabolic Drug Design and Targeting begins with an introductory chapter that explores new drugs and medical progress as well as the challenges of today's drug discovery. Next, it discusses: Basic concepts of the mechanisms of drug action Drug discovery and development processes Retrometabolic drug design Soft drugs Chemical delivery systems Inside the book, readers will find examples from different pharmacological areas detailing the rationale for each drug design. These examples set forth the relevant pharmacokinetic and pharmacodynamic properties of the new therapeutic agents, comparing these properties to those of other compounds used for the same therapeutic purpose. In addition, the authors review dedicated computer programs that are available to support and streamline retrometabolic drug design efforts. Retrometabolic Drug Design and Targeting is recommended for all drug researchers interested in employing this newly tested and proven approach to developing safe and effective drugs.

Neurological Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for neurological disorders such as neurofibromatosis, Alzheimer's disease, Parkinson's disease, Huntington disease, ALS, and the epilepsies. Neurological Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the second volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, which is also available for purchase individually. - Clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process - Critical evaluation of animal and translational models improving transition from drug discovery and clinical development - Emphasis on what results mean to the overall drug discovery process - Exploration of issues in clinical trial design and conductance in each therapeutic area

This book brings together the proceedings of Alzheimer's and Parkinson's Diseases: New Perspectives, the Sixth International Conference on Alzheimer's Disease and Parkinson's Disease, held recently in Seville, Spain, and discusses the latest developments in the basic science and therapy of Alzheimer's and Parkinson's diseases by leading specialists